ClinicalTrials.gg
CompletedNCT07845396JADESTRESSUpdated Sep 28, 2026

Assessment of Stress and Associated Factors Among Young Adults During the COVID-19 Pandemic

An observational study in Anxiety, Stress and COVID - 19, sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche. Completed at 1 site in France. Open to participants aged 18 Years to 29 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Primary conditionCOVID-19Registry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's title name COVID-19.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche · Observational

How we know

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
1,322
Ages
18 Years to 29 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 782 studies in COVID-19 with a site in France — 51 open to participants now, 68 under way, 7 of them phase 3. COVID-19 · France.

Enrollment
88th of 486
1,322 · median 298
Started
2022
with 58 others
Observational
486 of 782
27 open now
Registered
781st of 782
by date

Among the 782 studies in COVID-19 with a site in France, this one is the 88th largest by enrollment of the 486 observational ones that give a count, is one of 59 that started in 2022, is one of 486 observational ones, and was the 781st registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

51 of the 782 studies in COVID-19 with a site in France are open now. Recruiting first, the newest first:

46 more — sign in →

All 51 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 29 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 782 studies in COVID-19 with a site in France, or all of them as a file.
02

Study summary

Since the onset of COVID-19, studies conducted on the general population have shown an increase in the use of antidepressants and anxiolytics, a rise in domestic violence, and heightened demand for peri-urban housing offering more space and a better living environment.

Queues of students at food distribution points, along with the precarious situations and isolation faced by students with no alternative to cramped living quarters, have exposed the vulnerability of this population to the general public.

There is a lack of data regarding young people-and students in particular-a group known to be at higher risk than others of exhibiting symptoms of stress, anxiety, or depression.

Depression among students and young adults can impact their social lives, relationships, and quality of life. Indeed, studies have demonstrated a strong correlation between major depressive disorder and poor academic performance, unstable interpersonal relationships, suicidal thoughts and attempts, and difficulties with work.

Existing literature indicates a link between stress and the onset or persistence of anxiety and depression. As these conditions are too often conflated, it is important to distinguish stress from anxiety and depression.

Consequently, a study designed to assess levels of stress, anxiety, and depression-as well as the processes involved in their development and persistence among young people-would facilitate the implementation of appropriate and effective care.

Such a study is all the more necessary in the current context of the COVID-19 pandemic.

Identifying these disorders within specific populations and subgroups would enable the implementation of tailored care strategies, thereby helping to safeguard mental health.

The aim of this study is to assess current levels of stress, anxiety, and depression among young adults and students, and to investigate the underlying determinants.

03

Conditions studied

  • Anxiety
  • Stress
  • COVID - 19

Browse trials for

04

In context

COVID-19 Reclassified

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

This study's enrollment of 1,322 is above the median of 268 across 3,209 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

GCS Ramsay Santé pour l'Enseignement et la Recherche is the lead sponsor of 208 studies on the registry; 100 are open to participants now.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 29 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adult patient between 18 and 29 years old

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject between 18 and 29 years of age.
  • Subject capable of understanding the information necessary for the study and participating in online surveys.
  • Has read the information sheet describing the research and agreed to participate.
  • Subject affiliated with or a beneficiary of a social security scheme.

Exclusion criteria

Exclusion Criteria:

  • Minor subject
  • Subject aged 30 or older
  • Difficulty understanding and/or expressing themselves in French
  • Subject under legal protection measures (curatorship, guardianship, etc.) or deprived of liberty by judicial or administrative decision
  • Pregnant, breastfeeding, or recently delivered woman
06

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
1,322 participants (actual)
Patient registry
No

Groups and cohorts

  • patient between 18 and 29 years old

    Other: Questionnaire

Interventions

  • OtherQuestionnaire

    * Generalised anxiety disorder questionnaire * Questionnaire Patient Health Questionnaire-9 (PHQ-9) * Perceived Stress Scale questionnaire * Difficulties in Emotion Regulation Scale (DERS-16) questionnaire * Acceptance and action questionnaire * Perseverative Thinking Questionnaire * D-stress questionnaire * Electrostatic discharge questionnaire

07

What researchers measure

Primary outcomes

  1. Perceived Stress Scale (PSS) score :

    The PSS-10 takes about 3 minutes to complete and produces a 0-40 score : * 0-13 low * 14-26 moderate * 27-40 high

    Time frame: 3 months

08

Study locations

1 site
  • Université de Nanterre
    Nanterre, 92000, France
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Sep 2022, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Sep 28, 2026
StartActual
May 16, 2022
Primary completionActual
Sep 26, 2022
CompletionActual
Jan 27, 2023
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07845396
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
May 16, 2022
Primary completion
Sep 26, 2022
Completion
Jan 27, 2023
Last update
Sep 28, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion